CytRx raises money for oncology pipeline by selling off RXi stake
This article was originally published in Scrip
Executive Summary
CytRx has sold off its remaining stake in its RNAi spin-off RXi Pharmaceuticals, raising around $7 million. CytRx says the funds will support the clinical advancement of its oncology pipeline.